Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures read more

Read more on SYS-CON Media

FacebookShare